Torrent Pharmaceuticals Limited
TORNTPHARM · Pharma · NSE
₹4,473
Current Market Price
Fair Value (DCF)
₹1,605
Discount to FV
-64.1%
Updated 56m ago
YieldIQ Score
40/100
Piotroski F-Score
5/9
Economic Moat
Narrow
Confidence
64%
ROE
25.2%
Debt/Equity
0.42
WACC
9.5%
Market Cap
₹1.51 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
34.5%
Return on capital employed
EV / EBITDA
37.3×
Enterprise multiple
Debt / EBITDA
3.4×
Leverage vs earnings
Interest Coverage
8.5×
EBIT covers interest
Current Ratio
1.13×
Short-term liquidity
Asset Turnover
0.28×
Revenue per ₹ of assets
Revenue CAGR (3Y)
13.3%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹4,472.9
Bear case
Discount -397.8%
Base case
Discount -178.7%
Bull case
Discount -98.9%
Ratio Trends
TORNTPHARM · last 8 annual periods
ROE
25.2%
ROCE
34.5%
Operating Margin
—
Debt / Equity
0.42×
PE
181.3×
EV / EBITDA
18.9×
Historical Financials
TORNTPHARM · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹8419 Cr | ₹9464 Cr | ₹10.6K Cr | ₹11.3K Cr | ₹13.8K Cr | +13.1% |
| EBITDA | ₹2141 Cr | ₹2881 Cr | ₹3500 Cr | ₹3720 Cr | ₹4376 Cr | +19.6% |
| EBIT | ₹1481 Cr | ₹2180 Cr | ₹2706 Cr | — | — | +16.3% |
| PAT | ₹777 Cr | ₹1245 Cr | ₹1656 Cr | ₹1911 Cr | ₹2163 Cr | +29.2% |
| EPS (diluted) | ₹0.00 | ₹36.79 | ₹48.94 | — | — | — |
| CFO | ₹1803 Cr | ₹2368 Cr | ₹3266 Cr | ₹2585 Cr | ₹3023 Cr | +13.8% |
| CapEx | ₹-203 Cr | ₹-574 Cr | ₹-433 Cr | ₹-611 Cr | ₹-677 Cr | — |
| FCF | ₹1600 Cr | ₹1794 Cr | ₹2833 Cr | ₹1974 Cr | ₹2346 Cr | +10.0% |
| Total Assets | ₹13.1K Cr | ₹15.0K Cr | ₹15.1K Cr | ₹15.0K Cr | ₹44.3K Cr | +35.6% |
| Total Debt | ₹4070 Cr | ₹5369 Cr | ₹4022 Cr | ₹3202 Cr | ₹15.0K Cr | +38.6% |
| Shareholders' Equity | ₹5953 Cr | ₹6198 Cr | ₹6856 Cr | ₹7591 Cr | ₹8389 Cr | +9.0% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
TORNTPHARM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 DIVISLAB Divi's Laboratories Limited | -63.3% | 40 | Above Fair Value | 15.3% | 0.7× |
 LUPIN Lupin Limited | +35.6% | 50 | Near Fair Value | 23.8% | 19.8× |
 DRREDDY Dr. Reddy's Laboratories Limited | +19.7% | 55 | Near Fair Value | 11.4% | 24.4× |
 CIPLA Cipla Limited | -11.5% | 45 | Near Fair Value | 11.3% | 25.5× |
 ZYDUSLIFE Zydus Lifesciences Limited | +28.9% | 63 | Near Fair Value | 18.6% | — |
Click a ticker to view its fair-value analysis.
Dividend History
18 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹142.50/sh
Last payout
2026-02-18
₹29.00
Peak payout
₹29.00
Trailing yield
0.78%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Torrent Pharmaceuticals Limited (TORNTPHARM.NS) trades at 4472.90 vs a model fair value of 1605.17, a gap of -64.1%. Piotroski F-score: 5...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of TORNTPHARM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for TORNTPHARM →
Compare
Head-to-head with peers
Compare TORNTPHARM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse TORNTPHARMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.